BMS Bolsters Pipeline with Two Billion-Dollar Deals
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 6 (Table of Contents)
Published: 17 Jun-2021
DOI: 10.3833/pdr.v2021.i6.2613 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Bristol Myers Squibb has agreed to pay US$200 M upfront to access Agenus’ bispecific TIGIT antibody AGEN1777, which is currently in late preclinical development...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS